Timing of bone-modifying agents after bone metastasis diagnosis and time to first skeletal-related event: A systematic review and study-level correlation analysis
Journal of Oncology Pharmacy Practice
Published online on December 23, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionBone-modifying agents (BMAs) effectively prevent skeletal-related events (SREs) in bone metastases (BMs). While early BMA use is recommended upon BM diagnosis, its benefits and optimal timing remain unclear. This study investigated whether ...
IntroductionBone-modifying agents (BMAs) effectively prevent skeletal-related events (SREs) in bone metastases (BMs). While early BMA use is recommended upon BM diagnosis, its benefits and optimal timing remain unclear. This study investigated whether ...